You are here

Phen Tabz tablets

Safety advisory

2 December 2013

Phen Tabz tablets poses a serious risk to your health and should not be taken.

The Therapeutic Goods Administration (TGA) has tested Phen Tabz tablets which are indicated for weight loss and found that:

  • Phen Tabz bottlethey contain the undeclared substance of 1,3-dimethylamylamine (aka DMAA).
  • consumers are advised that DMAA is a toxic substance with dangerous side effects, and the use of DMAA in Australia is banned - The TGA decision to ban DMAA.

The supply of Phen Tabz tablets is illegal.

Phen Tabz tablets have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

TGA investigations have shown that a number of people in Australia have bought the product online.

Information for consumers

  • Phen Tabz supplement factsStop taking Phen Tabz tablets and take any remaining sachets to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with Australian Customs and Border Protection Services (Customs) to help stop future shipments of Phen Tabz tablets from entering Australia.

If these tablets are found at the border by Customs they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone: 1800 020 653
Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products